Pharming Group (NASDAQ:PHAR) Sees Large Growth in Short Interest

Pharming Group (NASDAQ:PHAR) was the recipient of a large increase in short interest in October. As of October 15th, there was short interest totalling 9,100 shares, an increase of 122.0% from the September 30th total of 4,100 shares. Based on an average trading volume of 7,500 shares, the short-interest ratio is currently 1.2 days.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a research report on Thursday.

Institutional Trading of Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its position in Pharming Group (NASDAQ:PHAR) by 75.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,110 shares of the company’s stock after buying an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.06% of Pharming Group worth $339,000 at the end of the most recent quarter. 0.03% of the stock is owned by hedge funds and other institutional investors.

Pharming Group Trading Up 4.8 %

Shares of PHAR stock traded up $0.40 during mid-day trading on Friday, hitting $8.70. The company’s stock had a trading volume of 6,324 shares, compared to its average volume of 4,887. The company’s fifty day simple moving average is $8.05 and its 200-day simple moving average is $8.54. Pharming Group has a 52 week low of $6.65 and a 52 week high of $13.20. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.65 and a current ratio of 3.39. The company has a market cap of $590.12 million, a PE ratio of -45.79 and a beta of 0.15.

Pharming Group (NASDAQ:PHAR) last issued its earnings results on Thursday, August 1st. The company reported ($0.01) EPS for the quarter. Pharming Group had a negative net margin of 4.65% and a negative return on equity of 5.69%. The firm had revenue of $74.09 million during the quarter, compared to the consensus estimate of $71.95 million. During the same period in the previous year, the firm earned $0.02 earnings per share. As a group, equities research analysts expect that Pharming Group will post -0.15 earnings per share for the current fiscal year.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.